Quanta Announces Formation of North American Medical Advisory Board
Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision to give control to dialysis users through more flexible and accessible dialysis care, announced today the formation of a North American Medical Advisory Board (MAB). This group of highly esteemed kidney care thought leaders will provide clinical expertise and guidance as Quanta brings its portable hemodialysis system SC+ to the United States market to enable greater flexibility in the delivery of life sustaining dialysis care.
The Medical Advisory Board consists of prominent nephrologists and is chaired by Dr. Paul Komenda, Chief Medical Officer (CMO) at Quanta. Bringing to bear extensive clinical and academic research, Dr. Komenda is a fellow of both the American Society of Nephrology and the Royal College of Physicians and Surgeons, Canada. Additionally, Dr. Komenda has authored and published over 160 peer-reviewed articles focusing on health services research, home dialysis and clinical nephrology.
I am thrilled to welcome this diverse group of nephrologists who are performing at the top of their field to our North American Medical Advisory Board. The Medical Advisory Board’s experience and insights will be critical as we explore how to best leverage the proven benefits of SC+ to serve patients and providers in the United States dialysis market.
Dr. Paul Komenda
Members of Quanta’s North American Medical Advisory Board include:
- Dr. Christos Argyropoulos, MD: Dr. Christos Argyropoulos is the division chief of nephrology at the University of New Mexico Health Sciences Center. He currently conducts research on kidney related biomarkers, middle molecule removal by dialysis platforms and big data. Dr. Argyropoulos’ clinical interests focus on outreach nephrology, home dialysis and diabetic kidney disease. Dr. Argyropoulos trained in internal medicine at the University of Cincinnati and in nephrology and transplant nephrology at the University of Pittsburgh Medical Center.
- Dr. Christopher Chan, MD, FRCPC: Dr. Chan is the divisional director of nephrology, professor of medicine, and holds the R Fraser Elliott Chair in Home Dialysis at the Toronto General Hospital, University Health Network in Canada. He is also the deputy physician in chief of economics at the University Health Network. He serves as associate editor for the Clinical Journal of the American Society of Nephrology. Dr. Chan joined the division of nephrology at Toronto General Hospital, University Health Network in 2002, after completing post-graduate training in internal medicine and nephrology at the University of Toronto. He has contributed over 200 peer-reviewed articles and has written extensively on home dialysis.
- Dr. Shaminder Gupta, MD: Dr. Gupta has been a practicing nephrologist in Louisiana for 17 years where he focuses on the long-term management of chronic kidney disease and end-stage renal disease. He has a special interest in population health and has SM-00146-A served as the state lead for hypertension and chronic kidney disease in Louisiana. He is currently the associate chief medical officer of Monogram Health, a kidney disease benefit management and care delivery company, and chief medical officer of Monogram Kidney Care Clinic, an in-home and virtual kidney clinic that provides leading care in 20 states. He previously served as president of the National Kidney Foundation of Louisiana and founded its home dialysis task force.
- Dr. Andrew E. Lazar, MD: Dr. Lazar is the chief of nephrology at Ahuja Medical Center in Ohio. In addition, he is medical director for Natera where he works to promote the use of genetic testing for kidney disease patients. He is also medical director at both Dialyze Direct and Renew Dialysis. He is the founder of Peloton Medical Devices, a medical engineering company focused on the development of a dialysis safety device. He also founded Cleveland Kidney Disease Associates and Affiliated Dialysis of Ohio, which is now owned and operated by Dialyze Direct. Affiliated Dialysis of Ohio was the first provider of home dialysis therapies in nursing home facilities for the state of Ohio. Dr. Lazar also started Cleveland Home Dialysis, one of the largest providers of home hemodialysis and peritoneal dialysis in Northeast Ohio.
- Dr. Bijal V. Patel, MD: Dr. Patel is the director of home therapies for Balboa Nephrology Medical Group (BNMG), chief of nephrology for Sharp Rees-Stealy and physician home champion for Fresenius Kidney Care. He previously served as medical advisor for Cricket Health. Through the practice of medicine, Dr. Patel strives to give patients the best opportunity to live well with kidney disease. By overcoming barriers, educating patients, and addressing social determinants of health, he achieves high rates of home modalities and living donor transplantation. Dr. Patel currently serves as chairman of the board for BNMG and was named San Diego’s top doctor in the field of nephrology by San Diego Magazine in 2020.
- Dr. Brigitte Schiller, MD: Dr. Schiller is CMO at Satellite Healthcare where she has been responsible for quality, physician leadership, and research and development since 2010. As CMO, Dr. Schiller leads efforts for the delivery of care to more than 8,000 dialysis patients with more than 20% of these patients undergoing home dialysis. She also serves as chief of staff and directs Satellite Healthcare’s clinical research efforts. Dr. Schiller has participated as investigator in multiple United States Food & Drug Administration (FDA) trials and is a published author in many areas of end-stage renal disease care, including home dialysis. She serves on the expert panel for the United States Renal Data System database.
The launch of Quanta’s North American Medical Advisory Board comes on the heels of the Company’s $245 million Series D funding round announced earlier this summer. This funding will accelerate Quanta’s global operational development and United States commercial roll-out, strongly positioning the company to pursue a $12 billion-dollar total addressable market opportunity in the United States alone.